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EXECUTIVE SUMMARY 
 
Introduction: Post-Operative Nausea and Vomiting (PONV) is a recurrent and frequent 
issue for the patient, the anesthesia team, and Post Anesthesia Care Unit (PACU) team.  
Both pharmacologic and non-pharmacologic recommended modalities have been utilized 
for both the prevention and treatment of PONV in the surgical-anesthesia setting. 
The 5-HT3-receptor antagonist ondansetron is one of the many known pharmacological 
modalities commonly utilized by anesthesia providers in preventing PONV. 
 
Methodology: The design used for this research was a quantitative, retrospective case 
control study that evaluated existing data enclosed in the Electronic Medical Records 
(EMR) from Charleston Area Medical Center (CAMC), which is made up of four 
hospitals.  The sample population included 89 patients: 64 patients with a BMI ≥ 30kg/m2 
who have received ondansetron 4 milligrams (mgs) and 25 patients with a BMI ≥ 
30kg/m2 who have received ondansetron 8 mgs.  In this sample population, all of the 
patients were 18 to 64 years of age with an American Society of Anesthesiologist (ASA) 
I-IV undergoing mastectomy.  
 
Results: There were no statistical significance found between the ondansetron dosage 
and the occurrence of PONV.  There were no statistical significance found between the 
two groups and BMI (p >.05).  The mean BMI for ondansetron 4 mgs group was 37 
kg/m2 and ondansetron 8 mgs group was also 37 kg/m2.  The mean dose of rescue 
antiemetic received in the PACU also did not show to be statistically significant between 
the two groups (p >.05). 
 
Discussion: Approximately 19% of the patients in this study experienced PONV despite 
the intra-operative administration of ondansetron.  There were no statistical significance 
that was found between the ondansetron dosing and PONV.  This may be the result that 
the dosing of ondansetron may truly not make a difference in preventing PONV. 
 
Conclusion: The outcome of this study did not express any statistically significant 
difference in the 4 mgs and 8 mgs dosing of ondansetron and the occurrence of PONV or 
the amount of rescue anti-emetic received in PACU. 
 
Practical Implications: The result of this study did not demonstrate any additional 
benefit from a larger dose of 8 mgs compared to a dose of 4 mgs of ondansetron.  Dosing 
4 mgs may just be as effective as 8 mgs, which simply brings to light that more is not 
simply better in all cases.  Further research is needed on this topic. 
 
Key Words: Post-operative nausea and vomiting, ondansetron, mastectomy, body mass 
index, rescue anti-emetic.
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INTRODUCTION 
 
Background and Significance of the Problem 
 
  
 Post-Operative Nausea and Vomiting (PONV) is a recurrent and frequent issue 
for the patient, the anesthesia team, and Post Anesthesia Care Unit (PACU) team.  Both 
pharmacologic and non-pharmacologic recommended methods have been utilized for 
both the prevention and treatment of PONV in the surgical-anesthesia setting.  The most 
common and distressing symptoms that follow surgery with the utilization of anesthesia 
include both emesis and pain (Gupta, Wakhloo, Lahori, Mahajan, & Gupta, 2007).  
Prevention and treatment of PONV in surgical procedures that are highly associated with 
this risk is usually at the discretion of the anesthesia provider of what they think is the 
best regimen for that patient type.  
 The adverse effects of PONV range from patient related distress to post-operative 
life threatening morbidities (Smith, Smith, & Smith, 2012).  Patients are willing to 
tolerate pain with a higher degree to that of PONV and often rate PONV as worse than 
post-operative pain (Gan, 2002).  It is not surprising that the prevention of PONV 
improves patient satisfaction by those who are highly at risk for it (Darkow, Gora‐
Harper, Goulson, & Record, 2001).  Patients were willing to pay United States (US) $56 
for an antiemetic that would completely prevent PONV and those who developed PONV, 
were willing to pay US $73 and $100 respectively (Gan, Sloan, de L Dear, El-Moalem, & 
Lubarsky, 2001).   
 Patients with no known risk factors carry a 10% risk of PONV, and this risk 
increases drastically to 61% and 79% respectively, when 3 or 4 risk factors exists (female 
gender, nonsmoker, history of motion sickness, post-operative opioid use, and a history 
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of PONV) (Roberts, Bezinover, & Janicki, 2012).  Despite the existence of various tools 
to categorize those at risk for developing PONV and implementing multiple PONV 
prevention and treatment regimens, clinicians do not appear to methodically address these 
issues in an identical approach that utilizes both non-pharmacologic and pharmacologic 
modalities to minimize PONV (Smith et al., 2012).  The research on PONV is vast and 
since it is so common, both the prevention and treatment modalities can range from non-
pharmacological to pharmacological, or both.  
Literature Review  
 Nausea and vomiting are amongst the most common post-operative disorders that 
can occur with various types of anesthesia.  The term nausea and vomiting are 
intertwined, but yet these remain two separate entities and should be evaluated 
individually.  Nausea is defined as a subjective unpleasant sensation in which the patient 
is aware of the desire to expel gastric contents, but does not necessarily do.  Vomiting is 
expressed as the expulsion of gastric contents orally by the physical motion of the 
contraction of the abdominal muscles, descent of the diaphragm, and opening of the 
gastric cardia (Golembiewski, Chernin, & Chopra, 2005).   
 Because of the physical and emotional stressors of PONV, these consequences 
can be seen as life –menacing to the patient.  Preventing PONV improves satisfaction 
scores among those patients who are at an increased risk of experiencing them  (Darkow 
et al., 2001).  Patients report the avoidance of pain is far less a concern than that of 
PONV and although rarely fatal, it can be uncomfortable and be associated with 
dissatisfaction with their peri-operative care (Rahmann & Beattie, 2004).  Some of these 
physical consequences of PONV include sweating, pallor, tachycardia, stomachache, 
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increased risk of esophageal rupture, wound dehiscence, and electrolyte imbalance 
(Gupta et al., 2007).  Multiple physical characteristics related with PONV may be mild, 
but the impact on patients and their recovery can be much more severe.  Some of these 
complications include the inability to mobilize after surgery, restricted oral intake, 
delayed recovery, and delayed discharge after surgery (Gan et al., 2007).  
 There are many risk factors and contributing factors that increase or add to the 
effects of PONV.  Pre-operative dehydration may occur due to the fact that pre-operative 
orders usually include directions to remain nothing-by-mouth (NPO), and can affect post-
operative consequences. Because of this NPO status, gut hypoperfusion may occur and is 
identified as one of the contributing factors to PONV.  To assist with mesenteric 
perfusion, likely to prevent PONV, preloading with large volumes of fluids is usually 
administered by anesthesia prior to induction (Chaudhary, Sethi, Motiani, & Adatia, 
2008).  Post-operative patients can have outcomes such as thirst, dizziness, and 
drowsiness, and nausea may be predisposed by the little to none patient’s fluid status 
intake before and after surgery.  The use of opioids in any phase of the surgery can 
produce nausea and vomiting by direct stimulation of the chemoreceptor trigger zone 
(CTZ), induced delayed gastric emptying, and decreased gastric motility (Bailey, Egan, 
& Stanley, 2000). 
 There are PONV scales available to determine risk factors and or the severity of 
PONV in the post-operative phase, which include the Apfel score and the Visual 
Analogue Scale (VAS).  The Apfel score considers four risk factors:  the female gender, 
previous history of PONV or motion sickness, non-smoking status, and post-operative 
use of opioids (Pierre, Benais, & Pouymayou, 2002).  Severity of nausea and vomiting is 
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assessed by the (VAS): Score 0- no nausea or vomiting, Score 1- nausea, Score 2- 
retching or mild vomiting, Score 3- two or more vomiting(s) in a 30 minute duration 
(Gupta, & Jain, 2014). 
 PONV is a common complication that patients experience following breast 
surgery (Watwill et al., 2003).  The stated occurrence of PONV in patients undergoing 
breast surgery with axillary dissection is about 60-80% (Fujii, 2006).  The pharmacologic 
drugs, which include 5-HT3 receptor antagonists, are widely used drugs given routinely 
by anesthesia providers as a first line modality in the prevention of PONV.  Because 
breast surgery is commonly associated with PONV, the modalities to help prevent and or 
treat PONV are comprised of multimodal therapies that utilize both non-pharmacological 
and pharmacological programs. 
 Many modalities to prevent and treat PONV have been utilized by anesthesia in 
recent decades.  Some non-pharmacologic and alternative techniques for the prevention 
and treatment of PONV include, but are not limited to, acupuncture, electro-acupuncture, 
acupoint stimulation, acupressure, transcutaneous nerve stimulation, ginger, hypnosis, 
and aromatherapy (Golembiewski, et al., 2005).  The most commonly used method to 
treat severe PONV is the administration of an intravenous (IV) anti-emetic agent that 
obstruct emetogenic neurotransmitters (NT) at the level of the CTZ located within the 
brain.  Some of these NT include serotonin (5-HT3), dopamine, histamine, and 
acetylcholine.  The introduction of 5-HT3 receptor antagonists was a major breakthrough 
in the 1990’s and represented a major development in pharmacotherapy in regards to 
treatment regimens that induced nausea and vomiting (Radford, Fuller, Bushey, Daniel, 
& Pellegrini, 2011).  Ondansetron was the first drug to be introduced and is the most 
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commonly used drug in the class of 5-HT3 receptor antagonists (Ku, & Ong, 2003). According to Golembiewski et al. (2005), the recommended dose for ondansetron in an adult is 4 milligrams (mgs), but Ku and Ong state that the optimal prophylactic intravenous dose of ondansetron is 8 mgs for long-term efficacy (Ku & Ong, 2003).  
The clinical side effect of the drug ondansetron includes the commonly reported 
headache and the ability to prolong the QT interval on the electrocardiogram 
(Butterworth, Mackey, Wasnick, Morgan, & Mikhail, 2013).  For these reasons, the clinician administering the drug must be vigilant in understanding the pharmacodynamics and clinical side effects of ondansetron.   In this study, the researcher planned to investigate a common prophylactic 
prevention and treatment of PONV utilized at Charleston Area Medical Center (CAMC) 
to determine if there was a decrease in the occurrence of PONV.   
Statement of the Problem and Research Purpose 
 PONV is a common issue at CAMC, and because there are a multitude of 
prevention and treatment regimens among varying anesthesia providers, an investigation 
of a commonly utilized prophylactic treatment was complete.  A mutual practice at 
CAMC is the administration of ondansetron 8 mgs in obese patients instead of the 
standard dose of ondansetron 4 mgs.   
 The purpose of this retrospective investigation is to determine if patients with a 
BMI ≥ 30kg/m2 undergoing mastectomy procedure, who have received ondansetron 4 
mgs intra-operatively, experienced more PONV than those who have received 
ondansetron 8 mgs.  
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  Another purpose of this investigation is to determine if obese patients with a BMI 
≥ 30kg/m2 who experienced PONV after receiving ondansetron 4 mgs intra-operatively, 
required more rescue anti-emetic medication than those who received ondansetron 8 mgs.   
 If this is so, facilities can possibly implement the use of 4 mgs of ondansetron 
instead of 8 mgs on patients with a BMI ≥ 30kg/m2 undergoing mastectomy, and can 
reduce the costs associated with the assumption that BMI’s ≥ 30kg/m2  require more 
pharmacological interventions.  By utilizing the minimal amount of ondansetron, needed 
to prevent PONV, can this also reduce the associated side effects seen with ondansetron? 
METHODOLOGY 
Research Hypothesis 
 This retrospective study was analyzed using the hypotheses: 1) In a group of ASA 
I-IV adult patients with a BMI ≥ 30kg/m2 undergoing a mastectomy procedure who 
received 4 mgs of ondansetron, there will be fewer incidences of PONV than those who 
received 8 mgs. 2) In a group of ASA I-IV adult patients with a BMI ≥ 30kg/m2 
undergoing a mastectomy procedure that received 4 mgs of ondansetron will require less 
amounts of rescue anti-emetic given than those who received 8 mgs. 
 
Research Design and Setting 
 The design used for this research was a quantitative, retrospective case control 
study evaluating existing data enclosed in the Electronic Medical Records (EMR) from 
Charleston Area Medical Center (CAMC), which is made up of four hospitals.   
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Sample Population with Description 
 The sample population used for this retrospective study included female patients 
who underwent a unilateral simple mastectomy and bilateral simple mastectomy at 
CAMC Health System between January 1, 2005 and June 1, 2015.  Males in this study 
were excluded due to only 10 males or 2 percent out of 363 charts were analyzed and 
only 3 males or 30 percent of all males made the inclusion criteria.  The sample included 
64 patients ages 18-64, measured in years, with a BMI greater than or equal to 30 kg/m2 
who received ondansetron 4 mgs and 25 patients with a BMI greater than or equal to 30 
kg/m2 who have received ondansetron 8 mgs.  The patients were identified using the 
following ICD10 procedure code: 85.41 unilateral simple mastectomy and 85.42 bilateral 
simple mastectomy.   
Inclusion Criteria: 
1. Adult patients 18 to 64 years of age. 
2. Patients with American Society of Anesthesiologists (ASA) physical status I-IV. 
3. Patients who underwent general anesthesia for mastectomy with a BMI greater 
than or equal to 30 kg/m2 and received either ondansetron 4 mgs or ondansetron 8 
mgs. 
 
Exclusion Criteria: 
1. Patients that have a history of PONV. 
2. Patients that have a history of a gastrointestinal (GI) disorders such as Crohn’s 
disease, Ulcerative Colitis (UC) or Irritable Bowel Syndrome (IBS). 
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3. Patients that received any other anti-emetic or medications that are known to have 
anti-emetic properties (i.e. Benadryl).  
4. Patients 17 years of age and younger or 65 years of age and older. 
5. Patients with an ASA physical status V-VI. 
6. Patients who underwent general anesthesia for mastectomy with a BMI less than 
30 kg/m2 and received either ondansetron 4 mgs or ondansetron 8 mgs. 
Procedure and Protocol 
 A retrospective chart review was completed on patient records that have 
undergone mastectomy at CAMC Health System from January 1, 2005 to June 1, 2015. 
To test the hypothesis, the following variables were collected: ondansetron dosage (4 mg 
versus 8 mg), BMI, occurrence of PONV, amount of rescue anti-emetic for PONV in the 
PACU, age, gender, and ASA status.  BMI is defined as a numeric calculation based on 
the patient’s weight and height for evaluation of patient’s body fatness for most people 
(CDC, 2015).  Nausea is defined as a subjective unpleasant sensation in which the patient 
is aware of the desire to expel gastric contents, but does not necessarily do.  Vomiting is 
expressed as the expulsion of gastric contents orally by the physical motion of the 
contraction of the abdominal muscles, descent of the diaphragm, and opening of the 
gastric cardia.  Obesity is identified as a BMI greater than or equal to 30kg/m2 and a BMI 
of greater than or equal to 30kg/m2 , is to be considered obese for this study (CDC, 2015).  
The utilization of rescue anti-emetic(s) is to be associated as a pharmacological agent(s) 
used for the treatment of PONV.  Age is to be labeled as 18 to 64 years.  Gender is to be 
classified as male or female.  Physical health status of each patient will be determined 
using ASA numerical scale from I-VI (ASA, 2015).  For the purpose of this study, 
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patients with a physical status of I-IV are to be incorporated.  The ASA classifications 
are: 
1. A normal healthy patient. 
2. A patient with mild systemic disease. 
3. A patient with severe systemic disease. 
4. A patient with severe systemic diseases that is a constant threat to life. 
Data Collection and Instruments 
 Data collection was conducted by using existing data from each patient’s 
individual EMR.  Each patient was given a number in the order in which the data was 
collected and the number in no way linked the data collected to the patient it belonged to.  
Individual data used was collected from the pre-operative anesthesia assessment flow 
sheet, anesthesia record, and the PACU patient documentation sheet.  
 Detailed data used was collected from the pre-anesthesia evaluation, anesthesia 
record and the PACU patient documentation during the patient’s time in the recovery 
phase at CAMC Health System.  The anesthesia record flow sheet used on each patient 
undergoing anesthesia at CAMC contained enclosed information including: surgical 
procedure, significant times in the operating room, medications administered, vital trends, 
and other patients’ surgical data.  The PACU at CAMC General, Memorial, Woman and 
Children’s, and Teays Valley hospitals cares for the patient’s needs immediately after 
surgery until patients have stabilized and are able to be transferred to a nursing floor or 
discharged home.  
 The PACU flow sheet was used to record patient data during the time that the 
patient was in the recovery room after surgery.  The PACU flow sheet enclosed material 
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that was collected for the study including: the occurrence of nausea and vomiting and the 
dosages of the rescue anti-emetic administered.  
 Data collection worksheets were established to aid in collection and organization 
of patient data.  Data Collection Worksheet 1 was used to assign each patient a study 
participant number that was linked to each patient’s identification number in order to 
protect patient identity (Appendix A).  Data Collection Worksheet 2 served to organize 
data for gender, age, height, weight, ASA, ondansetron dosage intra-operatively, 
occurrence of PONV, amount and usage of rescue antiemetic (Appendix B).  All data 
collected were recorded using these two data collection tools designed by the researcher 
for this study. 
Statistical Design and Analysis 
  The purpose of this study was to determine if patients with a BMI ≥ 30kg/m2 
undergoing mastectomy procedure, who have received ondansetron 4 mgs intra-
operatively, experienced more PONV than those who have received ondansetron 8 mgs.  
Another purpose of this investigation was to determine if obese patients with a BMI ≥ 
30kg/m2 who experienced PONV after receiving ondansetron 4 mgs intra-operatively, 
required more rescue anti-emetic medication than those who received ondansetron 8 mgs.  
Independent variables in this study included: age, BMI, ASA physical status, and 
ondansetron dosage.  Dependent variables analyzed were: PONV and dosage of rescue 
antiemetic required for relief of PONV.  
 The Pearson Chi-square was used to determine if there was a statistical significant 
difference between the ondansetron dosing groups with regards to physical status.  The 
Fisher’s exact test was used to assess the statistical significance 
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of the occurrence of PONV and ondansetron  dosing of 4 mgs and 8 mgs. 
A student t-test was used to determine if there was a statistical significant 
association between the two groups in regards to age and BMI.  A student t-test was used 
to determine the difference between the mean doses of ondansetron and promethazine 
received in the PACU between both groups.  A logistical regression was used to 
determine if there was a relationship between ondansetron dosage intra-operative and the 
occurrence of PONV, age, BMI, and ASA.  The logistical regression was again used to 
determine if there was an association between the rescue anti-emetic dose of 
promethazine and ondansetron and the intra-operative dose of ondansetron, age BMI, and 
ASA.  The level of statistical significance was set at p < .05. 
Ethical Considerations 
 This study was approved by CAMC and West Virginia University/Charleston 
Division Institutional Review Board on September 1, 2015 (Appendix C). 
 
RESULTS 
 
The mean age of all patients was 53 years with 100% of the population being 
female.  From a total of 89 patients that were included in the study, 71% of patients 
received ondansetron 4 mgs dosing intra-operatively (ondansetron 4 mgs group) and 28% 
of patients received ondansetron 8 mgs dosing intra-operatively (ondansetron 8 mgs 
group), (Table 1).  The independent samples t-test did not show a statistically significant 
difference between the mean age between ondansetron 4 mgs and ondansetron 8 mgs 
groups (p >.05),  
 The mean BMI for all patients was 37 kg/m².  The mean BMI of patients 
receiving ondansetron 4 mgs was 37 kg/m² while the mean BMI of patients receiving 
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ondansetron 8 mgs was also 37 kg/m². The independent samples T-test did not show a 
statistically significant difference between the mean BMI between ondansetron 4 mgs 
and ondansetron 8 mgs groups (p >.05), (Table1). 
 Most of the total patients in the study were ASA status II and III classifications 
(Table 1). Thirty- four percent of the total patients in the study were ASA I and II 
classifications, with 32% receiving ondansetron 4 mgs and 40 % receiving ondansetron 8 
mgs.  Fifty-eight of the total patients in the study were ASA III and IV classification, 
with 67% receiving ondansetron 4 mgs and 60% receiving ondansetron 8 mgs (Table 1).  
The Pearson Chi-square test did not show a statistically significant difference between the 
ASA status between ondansetron 4 mgs and ondansetron 8 mgs groups (p >.05), 
(Table1). 
Table 1:  Clinical Characteristics of Female Patients Undergoing Mastectomy Receiving 
Intraoperative Ondansetron 4 milligrams and Ondansetron 8 milligrams 
 
*Indicates Statistical Significance at p < .05, NS = Not Significant, kg/m²=kilograms per 
meters squared. Fisher’s Exact not completed for cells less than 5.  T Indicates T-test        
  TT  Indicates Pearson Chi-square test 
Variable Total                 (N= 89) 
Ondansetron 
4mgs           
(N=64) 
Ondansetron 
8mgs           
(N=25) 
P-
Value 
Age (years)     
Mean Age 53 53 52 NS T 
Gender     
Female 89 (100) 
64 
(100%) 
25 
(100%) NS
TT 
BMI (kg/m²)     
Mean BMI 37 37 37 NST 
ASA Physical Status 
Classification     
I & II 31 (34%) 
21 
(32%) 
10 
(40%) NS
TT 
III & IV 58 (65%) 
43 
(67%) 
15 
(60%) NS
TT 
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 Seventeen total patients experienced PONV in the study (Table 2).  Twenty- three 
percent of patients who received ondansetron 4 mgs intra-operatively experienced PONV 
compared to 8% of patients who received 8 mgs ondansetron intra-operatively (Table 2). 
The difference in the occurrence of PONV between the patients who received 
ondansetron 4 mgs and ondansetron 8 mgs intra-operatively was not found to be 
statistically significant (p >.05), (Table 2). 
Table 2: Comparison Between Patients Receiving Ondansetron 4 milligrams and 
Ondansetron 8 milligrams and Occurrence of Post-operative Nausea and Vomiting 
Utilizing the Fisher’s Exact Test 
*Indicates Statistical Significance at p < .05, NS = Not Significant, PONV = Post    
operative Nausea and Vomiting, mgs = milligrams 
 
Seventeen total patients in the study experienced PONV and most received a 
rescue anti-emetic (Table 3 a).  Fifteen of these patients were in the ondansetron 4 mgs 
group and received an average dose of 4.16 mgs of promethazine (Table 3 a).  Two 
whom experienced PONV were in the ondansetron 8 mgs group and received an average 
dose of about 1.68 mgs of promethazine (Table 3 a).  In a t-test comparison, there were 
no statistically significant differences in the dosing of promethazine rescue anti-emetic 
between these groups (p >.05), (Table 3 a). 
 
 
Variable Total                                     (N = 89) 
Ondansetron  4 mgs               
(N = 64) 
Ondansetron  8 mgs  
(N = 25) 
P-
Value 
Occurrence of 
PONV     
Yes 17 (19%) 
15 
(23%) 
2 
(8%) NS 
No 72 (80%) 
49 
(76%) 
23 
(92%)  
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Table 3 a: A T-test Measuring Association Between Dosing of Promethazine for Rescue 
Anti-emetic in Post-Anesthesia Care Unit Between Patients Receiving Ondansetron 4 
milligrams and Ondansetron 8 milligrams 
 
 
 
 
 
 
*Indicates Statistical Significance at p < .05, NS = Not Significant, mgs = milligrams 
  
Seventeen total patients in the study experienced PONV and received rescue 
antiemetic (Table 3 b).  Fifteen of these patients were in the ondansetron 4 mgs group and 
received an average dose of 1.86 mgs of ondansetron in the PACU (Table 3 b). Two 
whom experienced PONV were in the ondansetron 8 mgs group and received an average 
dose of 0 mgs of ondansetron in the PACU (Table 3 b). 
Table 3 b: A T-test Measuring Association Between Dosing of Ondansetron for Rescue 
Anti-emetic in Post-Anesthesia Care Unit Between Patients Receiving Ondansetron 4 
milligrams and Ondansetron 8 milligrams 
 
Variable Total                                     (N = 17) 
Ondansetron 
dose (mgs),           
Mean 
Intra-operative 
Ondansetron 
dosing 
  
4 mg 15 1.86 
8 mg 2 0 
 
 
 The Binary Logistic Regression analysis showed that there were no statistical 
significant associations between PONV and  those who received rescue anti-emetic, and 
Variable Total                                     (N = 17) 
Promethazine 
dose (mgs),           
Mean 
Std. 
Deviation 
P-
Value 
Intra-operative 
Ondansetron 
dosing 
    
4 mgs 15 4.16 4.5 NS 8 mgs 2 1.68 2.3 
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the rest of the variables: age, BMI, ASA, ondansetron intra-operative dose (p >.05), 
(Table 4). 
Table 4: Using Binary Logistic Regression for Post –Operative Nausea and Vomiting in 
Females Undergoing Mastectomy Receiving Rescue Anti-emetic Analysis 
Indicates Statistical Significance at p < .05, kg/m²=kilograms per meters squared, mgs = 
milligrams, (-) = no value indicated, NS= Not Significant 
 
The Binary Logistic Regression analysis showed that there were no statistical 
significant association between PONV and the rest of the variables:  age, BMI, or 
ondansetron intra-operative dose (p >.05), (Table 5). 
 
 
 
 
 
 
 
 
 
Step 1 B 
 
S.E 
 
Wald df Sig. 
 
 
Exp 
(B) 
 
 
Sig. 
(2-
tailed) 
95% 
Confidence 
Interval of 
the 
Difference 
(Upper) 
 
 
P-Value 
Age (years) 
-.030 .036 .722 1 .395 .970 
 
.415 
 
5.2659 
  
 
NS 
BMI (kg/m²) 
-.034 .047 .505 1 .477 .967 
 
.937 
 
3.0487 
  
 
NS 
ASA .368 .549 .450 1 .502 1.445 - - NS 
Ondansetron 
dose in mgs .314 .201 2.429 1 .119 .731 
- -  
NS 
Constant 2.002 2.963 .457 1 .499 7.404 - - NS 
Rescue drug 
Promethazine 
in mgs 
- - - - - - 
 
.139 
 
1.9674  
 
 
NS 
Rescue drug 
Ondansetron 
in mgs 
- - - - - - 
 
.087 
 
.93945  
 
 
NS 
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Table 5: Using Binary Logistic Regression for Post –Operative Nausea and Vomiting in 
Females Undergoing Mastectomy Analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Indicates Statistical Significance at p < .05, NS = Not Significant, kg/m²=kilograms per 
meters squared, mgs = milligrams, (-) = no value indicated 
 
DISCUSSION 
Discussion of Study Results 
 Despite all of the female patients in this study receiving an intra-operative dosing 
of ondansetron, about 19% still experienced PONV and is consistent with current 
literature that being a female is a risk factor that increases the risk for PONV  (Eberhart, 
et al., 2004). The independent samples T-test did not show a statistically significant 
difference association between the mean age and BMI between ondansetron 4 mgs and 
ondansetron 8 mgs groups.  The Pearson Chi-square test did not show a statistically 
significant difference in association between the ASA physical status and ondansetron 4 
mgs and ondansetron 8 mgs groups.  Literature studies correlate that the BMI and ASA 
physical status is not a significant predictor of PONV, but according to the Apfel risk 
 
B 
95% 
Confidence 
Interval of 
the 
Difference 
(Upper) 
 
P-Value 
(Constant) 2.002 - NS 
Age (years) -.030 5.2659 NS 
BMI 
(kg/m²) -.034 
3.0487 NS 
Ondansetron 
4 mgs 
Ondansetron 
8 mgs 
-.314 
 
- NS 
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model for the probability of PONV, female gender, non-smoking, history of PONV, and 
the use of post-operative opoids are (Choi, Ko, Ahn, & Kim, 2005).   
 The Fisher’s exact test was used to determine if there was an association between 
ondansetron dosing and the occurrence of PONV, but there was no statistical 
significance.  Per existing literature, ondansetron is recommended to be given at the end 
of the case and not at the start of it, and some of the patients were noted to have an intra-
operative dose at the start of the case, which may contribute to why some patients still 
developed PONV despite receiving a dose of intra-operative ondansetron (Quaynor & 
Raeder, 2002).  Another plausibility concluding that there was no statistical significance 
association between dosing and PONV may have been that 8 mgs of ondansetron offers 
no greater efficacy than 4 mgs intravenously as evidenced by standing literature 
(Golembiewski, Chernin, & Chopra, 2005).  In this instance, more of ondansetron may 
not simply mean there will be a lesser chance of PONV.  
 There was no statistically significance found between the intra-operative 
ondansetron dosing groups and the mean doses of rescue anti-emetics (promethazine/ 
ondansetron) received in the PACU utilizing the T-test formula.  This could perhaps be 
expounded by other treatment modalities performed by the PACU team such as 
intravenous fluids, application of supplemental oxygen, or treatment of a low blood 
pressure, which can contribute to nausea and vomiting.  Existing literature states that 
non-pharmacological modalities such as hydration and maintaining blood pressure have 
been shown to be effective in treating and preventing PONV (Golembiewski & O’Brien, 
2002).  
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 The result of the binary logistical regression analysis showed that there was not a 
statistical significant association between PONV and the rest of the variables: age, BMI, 
or ondansetron dosing.  As evidenced by literature studies, there may be no association 
between PONV and the variables age and BMI, suggesting that ondansetron dosing may 
not make a difference in the occurrence of PONV (Jaffe, Campbell, Bellman, & Baildam, 
2000).  
 The outcome of the binary logistical regression analysis showed that there was not 
a statistical significant association between the administration of rescue anti-emetic 
dosing and the rest of the variables: age, ASA, BMI, or intra-operative ondansetron 
administration.  A multi-modal approach to decrease PONV involves the utilization of 
both pharmacological and non-pharmacological prophylaxis to reduce the baseline risk 
such as hydration, oxygen, and blood pressure support, which is a continuation modality 
in the PACU setting where the rescue anti-emetic dose would be administered (Gan et al., 
2007).  This may suggest that the dosing of the rescue anti-emetic when PONV is present 
had no association with the intra-operative dosing of ondansetron, age, ASA, or BMI. 
Study Limitations 
A limitation to this retrospective study would consist that this may not provide 
definite information about the cause-and-effect relationship.  A more causal type of 
design would consist of a longitudinal study, which is observational like the cross-
sectional design, except these studies extend beyond a single moment and can establish 
sequence of events (IWH, 2015).  Errors and omissions can result in poor documentation 
and or misinterpretation of data, especially in a retrospective study. 
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 A total of 363 charts were analyzed due to only 363 patients were coded for the 
two ICD 10 codes of 85.41 and 85.42. between January 1, 2005 to June 1, 2015, and only 
89 charts or 24% of them met the inclusion criteria requirements.  Out of the 363 charts, 
only 10 were male or 2%, and because of a small percentage that made the inclusion 
criteria, there were not any male patients that were included in the study.  Mastectomies 
in males, for the treatment of breast cancer, is rare due to the disease in males is 
uncommon and accounts for only one percent of all breast cancers diagnosed in the world 
wide annually (Korde et al., 2010).  
 Another limitation in this study includes a skewed amount of ondansetron given 
in which 71% of the patients received 4 mgs and only 28% received 8 mgs in the 89 
patients that were part of the inclusion criteria. This may have been due to provider 
preference due to caution taken with higher doses as to minimize the side-effect 
associated with ondansetron, which most commonly is that of a QT interval prolongation 
on an electrocardiogram reading (Kator, & Kim, 2015).  
 When assessing all 89 charts, there was not a single patient that received more 
than 8 mgs of ondansetron, including the pre-operative, intraoperative, and postoperative 
periods, and this may be associated with that 8 mgs may be the maximum one feels 
confortable giving because of the unwanted side-effects or they may assume it is not 
effective and or switch to another anti-emetic.  According to the US Food and Drug 
Administration (FDA), an update in 2012 states that GlaxoSmithKline (GSK) has 
announced changes to the label of the drug Zofran or ondansetron, stating its use in adults 
and children with chemotherapy-induced nausea and vomiting at the lower intravenous 
dose recommended in the drug label, a dose of 0.15 mg/kg administered every 4 hours for 
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three doses. High doses of ondansetron, such as 32 mgs in a single intravenous 
administration may affect the electrical activity of the heart and can pre-dispose the 
patient to abnormal or potentially fatal heart rhythms (FDA, 2011).  Because of the risk 
of pre-disposing patients to unwarranted side-effects associated with higher dosages of 
ondansetron within the perioperative period, of those patients who received 8 mgs 
intraoperative, they were not given an additional dose of ondansetron as a rescue anti-
emetic in PACU and instead promethazine was given, causing the data to be skewed with 
zero patients receiving ondansetron. 
 An additional limitation could have been poor documentation on the PACU flow 
sheet was a common trend noticed, possibly related to charting in 15 minutes increments 
such as inconsistencies with anti-emetic given, but there was no indication of PONV.   
Poor quality or missing information may significantly affect the results of a retrospective 
statistical investigation (Braaf, Manias, Riley, 2011). 
  Additional treatment modalities in the anesthesia-surgical setting and or PACU 
may have helped with the prevention and or treatment of PONV including but not limited 
to, anxiolytic administration, low-dose of neuromuscular blocking drug such as 
neostigmine, which in high-doses can cause PONV, and adequate intravenous fluid 
resuscitation of crystalloids and colloids (Chandrakantan, & Glass, 2011).  These 
influences were not examined as part of this study, which thereby could amend the 
results. 
 
CONCLUSION 
 
There was not any statistically significant difference in the 4 mgs and 8 mgs dosing of 
ondansetron and the occurrence of PONV or the amount of rescue anti-emetic received in 
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PACU.  In this study, 4 mgs ondansetron intra-operatively dosing was associated with the 
same prevention of PONV and utilization of rescue anti-emetics compared to the 8 mgs 
dosing of ondansetron.  
 
IMPLICATIONS AND RECOMMENDATIONS 
Prevention of PONV is crucial for both the patient’s safety and satisfaction enduring any 
surgical procedure.  Multimodal prevention and treatment modalities are at the discretion 
of the anesthesia provider, and the norm of the environment may also affect their choices.  
Dosing 4 mgs may just be as effective as 8 mgs, which simply brings to light that more is 
not simply better in all cases.  The results of this study can allow for a more cost-effective 
treatment plan when utilizing the drug ondansetron resulting in cost savings for both the 
facility and patient, and decrease associated side effects seen with higher dosing of 
ondansetron.  The study of this research may contribute to the anesthesia providers in 
planning appropriately for each individual patient in the prevention of PONV.  Further 
research is needed on this topic.  
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APPENDIX A: DATA COLLECTION WORKSHEET #1 
 
 
 
PIN# Study Participant # 
 1 
 2 
 3 
 4 
 … 
 89 
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APPENDIX B: DATA COLLECTION WORKSHEET #2 
 
 
 
 
 
 
 
 
 
 
 
 
Study 
Participant 
# 
Gender Age BMI ASA 
Physical 
Status 
I-IV 
Ondersetron 
Dose 
Intra-op 
Occurrence 
of 
PONV 
Y=yes 
N= no 
Promethazine 
in 
PACU 
(mgs) 
Ondansetron 
in 
PACU 
(mgs) 
1         
2         
3         
4         
…         
89         
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